Mikhail Blagosklonny is a scientist who studies cancer and aging. He was formerly a professor of oncology at the Roswell Park Cancer Institute in New York.
Blagosklonny earned both his M.D. in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Peterburg. He was appointed associate professor of medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (Albany, New York). Blagosklonny held this position until 2009 when he was appointed professor of oncology at Roswell Park Cancer Institute.
Blogosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs.
Rapamycin and aging
Blagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension. He is considered one of the most passionate advocates for rapamycin in longevity research.
Blagosklonny is editor-in-chief of Aging, Cell Cycle, and Oncotarget. In addition, he is associate editor of Cancer Biology & Therapy and a member of the editorial board of Cell Death & Differentiation.
The reviewing process employed by Oncotarget has been criticized by Jeffrey Beall, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals" in July 2015. Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editor-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal impact factor.
Blagosklonny has published over 270 papers in peer-reviewed journals with over 25,000 citations, giving him an h-index of 83.
Blagosklonny, MV (Dec 2013). "TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists". Nature Cell Death & Disease. 4: e964. PMC 3877573 . PMID 24336084. doi:10.1038/cddis.2013.506.
Leontieva, OV; Demidenko, ZN; Blagosklonny, MV (Jun 2014). "Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program". PNAS. 111 (24): 8832–7. PMC 4066505 . PMID 24889617. doi:10.1073/pnas.1405723111.
Hypoxia, Blagosklonny MV. (Feb 2013). "MTOR and autophagy: converging on senescence or quiescence". Autophagy. 9 (2): 260–2. PMC 3552896 . PMID 23192222. doi:10.4161/auto.22783.
Leontieva, OV; Natarajan, V; Demidenko, ZN; Burdelya, LG; Gudkov, AV; Blagosklonny, MV (Aug 2012). "Hypoxia suppresses conversion from proliferative arrest to cellular senescence". PNAS. 109 (33): 13314–8. PMC 3421205 . PMID 22847439. doi:10.1073/pnas.1205690109.
Leontieva, OV; Demidenko, ZN; Gudkov, AV; Blagosklonny, MV (2011). "Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin". PLoS One. 6 (10): e26126. PMC 3191182 . PMID 22022534. doi:10.1371/journal.pone.0026126.
Demidenko, ZN; Fojo, T; Blagosklonny, MV (Apr 2005). "Complementation of two mutant p53: implications for loss of heterozygosity in cancer". FEBS Letters. 579 (10): 2231–5. PMID 15811347. doi:10.1016/j.febslet.2005.03.012.
Blagosklonny, MV (2003). "Matching targets for selective cancer therapy". Drug Discov. Today. 8: 1104–7. PMID 14678733. doi:10.1016/s1359-6446(03)02806-x.
Giannakakou, P; Nakano, M; Nicolaou, KC; O'Brate, A; Yu, J; Blagosklonny, MV; Greber, UF; Fojo, T (August 2002). "Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics". PNAS. 99: 10855–60. PMC 125062 . PMID 12145320. doi:10.1073/pnas.132275599.
Blagosklonny, MV (2002). "Oncogenic resistance to growth-limiting conditions". Nature Reviews Cancer. 2: 221–5. PMID 11990858. doi:10.1038/nrc743.
Blagosklonny, MV (Apr 2002). "STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'". Nature Leukemia. 16 (4): 570–2. PMID 11960334. doi:10.1038/sj.leu.2402409.
Blagosklonny, MV (Apr 2002). "Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs". Nature Leukemia. 16 (4): 455–62. PMID 11960322. doi:10.1038/sj.leu.2402415.
Blagosklonny, MV. Pardee AB. (Mar 2002). "Conceptual biology: unearthing the gems". Nature. 416 (6879): 373. PMID 11919607. doi:10.1038/416373a.
Blagosklonny, MV; Fojo, T; Bhalla, KN; Kim, JS; Trepel, JB; Figg, WD; Rivera, Y; Neckers, LM (2001). "The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy". Leukemia. 15: 1537–43. PMID 11587211. doi:10.1038/sj.leu.2402257.
Blagosklonny, MV (2001). "Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells". Leukemia. 15: 936–41. PMID 11417480. doi:10.1038/sj.leu.2402127.
Blagosklonny, MV (2001). "Unwinding the loop of Bcl-2 phosphorylation". Leukemia. 15: 869–74. PMID 11417471. doi:10.1038/sj.leu.2402134.
